# EDGAR Filing Document

**Accession Number:** 0000911216
**File Stem:** 0001493152-26-024219
**Filing Date:** 2026-5
**Character Count:** 11084
**Document Hash:** eaf8722bbe977c4180db01297dbf0113
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-024219.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001493152-26-024219

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260518

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PALATIN TECHNOLOGIES INC
- **CENTRAL INDEX KEY:** 0000911216
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 954078884
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15543
- **FILM NUMBER:** 26994805

**BUSINESS ADDRESS:**
- **STREET 1:** 4B CEDAR BROOK DRIVE
- **CITY:** CRANBURY
- **STATE:** NJ
- **ZIP:** 08512
- **BUSINESS PHONE:** 609-495-2200

**MAIL ADDRESS:**
- **STREET 1:** 4B CEDAR BROOK DRIVE
- **CITY:** CRANBURY
- **STATE:** NJ
- **ZIP:** 08512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERFILM INC
- **DATE OF NAME CHANGE:** 19930825

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 18, 2026

---

| |
|:---|
| **PALATIN TECHNOLOGIES, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15543** | **95-4078884** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **301 Carnegie Center Drive, Suite 304, Princeton, NJ** | **08540** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **<u>(609) 495-2200</u>**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol | Name of each exchange on which registered |
| **Common Stock, par value $0.01 per share** | **PTN** | **NYSE American** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 3.01.** | **Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** |

---

On May 18, 2026, Palatin Technologies, Inc. (the "Company"), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the "NYSE") that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the "common stock"), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital Market (the "Nasdaq"). The Nasdaq has approved such listing. The Company expects the listing and trading of its common stock on the NYSE to cease at the close of trading on May 28, 2026. The Company expects the common stock to begin trading on the Nasdaq on May 29, 2026. The common stock will continue to trade under the symbol "PTN".

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.** |

---

The Company issued a press release on May 18, 2026 announcing the transfer of the listing of its common stock from the NYSE to Nasdaq. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in Item 7.01, including Exhibit 99.1, of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item** **9.01** | **Financial Statements and Exhibits.** |

---

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated May 18, 2026.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: May 18, 2026 | **PALATIN TECHNOLOGIES, INC.** |
|  | */s/ Stephen T. Wills* |
|  | Stephen T. Wills, CPA, MST |
|  | Executive Vice President, Chief Financial<br> Officer and Chief Operating Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Palatin to Begin Trading on Nasdaq Stock Exchange**

PRINCETON, NJ – May 18, 2026 /PRNewswire/ – Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

The Company expects to begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol "PTN." Palatin's common stock will continue to trade on the NYSE American until the market close on May 28, 2026.

"We are pleased to announce our listing on the Nasdaq Capital Market and to join a community of leading biotechnology companies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "We believe the move to Nasdaq will improve the visibility of our common stock, enhance trading liquidity in our shares, and provide us with greater exposure to institutional investors."

Palatin is advancing selective MC4R-based obesity programs targeting rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a focus on improved tolerability and long-term use. The Company's once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of calendar 2026, and its oral MC4R selective agonist program continues to advance, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027. Palatin's development strategy is focused on advancing potential best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use.

No action is required by existing stockholders with respect to the transfer of the Company's listing.

**About Palatin**

Palatin is a biopharmaceutical company developing medicines that target the melanocortin receptor system with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form collaborations with industry leaders to maximize their commercial potential. For more information, visit the company's website at <u>www.palatin.com</u> and follow us on X, formerly Twitter, @PalatinTech.

*-More-*

**<u>Forward-looking Statements</u>**

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about the commencement of trading of Palatin's common stock on the Nasdaq Capital Market. Palatin products in development, clinical trial results, potential actions by regulatory agencies, regulatory plans, development programs, proposed indications for product candidates, and market potential for product candidates are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating events that occur after the date of this press release.

---

| | |
|:---|:---|
| **Investor Inquiries:** | **Media Inquiries:** |
| Stephen T. Wills, CPA, MST | Paul Arndt, MBA, LifeSci Advisors, LLC |
| Chief Financial Officer/Chief Operating Officer | Managing Director |
| Tel: (609) 495-2200 / Info@palatin.com | Tel: (646) 597-6992 / Paul@LifeSciAdvisors.com |

---

Palatin Technologies<sup>®</sup> is a registered trademark of Palatin Technologies, Inc.

*###*